About NeoGenomics
What NeoGenomics is building
Technologies used at NeoGenomics
C
C++
Python
K8s
AWSCompany culture
Quality
We listen and respond to our customers
Integrity
Our reputation is the most valuable asset
Funding rounds
Total Funding
Last funding round type
Company type
NeoGenomics news and updates
Neogenomics Inc has issues with failing to disclose material information during the Class Period, violating federal securities laws
NeoGenomics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
Dec 22, 2022 | prnewswire.comBronstein, Gewirtz & Grossman, LLC files suit against Neogenomics Inc
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NeoGenomics, Inc. ("NeoGenomics" or the "Company) (NASDAQ: NEO ) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired NeoGenomics common stock between February 27, 2020 through April 26, 2022, inclusive (the "Class Period").
Dec 12, 2022 | prnewswire.comGlancy Prongay & Murray LLP acquires Neogenomics Inc
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO ) securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”).
Dec 9, 2022 | businesswire.comInvestingLab.com acquires Neogenomics Inc
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired NeoGenomics, Inc. ("NeoGenomics" or the "Company")
Dec 8, 2022 | benzinga.comGibbs Law files suit against Neogenomics Inc
Gibbs Law Group announces that it has filed a class action lawsuit against NeoGenomics Inc. (NASDAQ: NEO) and certain of its officers and directors on behalf of investors who purchased NeoGenomics securities from February 27, 2020 through April 26, 2022, inclusive.
Dec 7, 2022 | pharmiweb.comNeogenomics Inc hired Jeffrey S. Sherman as Chief Financial Officer on Dec 7th 22'.
NeoGenomics ( NASDAQ: NEO ) on Monday said that Jeffrey S. Sherman will join the company as CFO effective December 7, 2022.
Dec 6, 2022 | seekingalpha.comNeogenomics Inc partnered with ImmunoGen, Inc. on Nov 18th 22'.
NeoGenomics said Friday that it has partnered with ImmunoGen to launch a biomarker testing program for patients with epithelial ovarian cancer, identifying patients whose tumors express the folate receptor alpha (FRα) protein.
Nov 17, 2022 | genomeweb.comNeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing.
Jan 11, 2022 | BioSpaceNeogenomics Inc hired Bonello as President of the Informatics division, Chief Strategy and Corporate Development Officer and Director of Investor Relations on Jan 1st 17'.
Mr. Bonello, CFO, joined NeoGenomics in 2017 and has served as President of the Informatics division, Chief Strategy and Corporate Development Officer and Director of Investor Relations.
Jan 1, 2022 | streetinsider.comNeogenomics Inc has issues with securities fraud or other unlawful business practices
The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | globenewswire.comNeogenomics Inc has issues with potential violations of the federal securities laws
Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, announces that it is investigating NeoGenomics Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) for potential violations of the federal securities laws.
Jan 1, 2022 | bakersfield.comNeogenomics Inc hired Vishal Sikri as President and Chief Commercial Officer on May 9th 22'.
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris.
Jan 1, 2022 | biospace.comNeogenomics Inc has issues with potential breaches of fiduciary duties
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at NeoGenomics, Inc.
Jan 1, 2022 | openpr.comNeogenomics Inc hired Chris Smith as CEO on Jul 22nd 22'.
NeoGenomics has appointed Chris Smith as CEO and a member of its board of directors effective Aug. 15.
Jan 1, 2022 | genomeweb.comCardoza leaves Neogenomics Inc as President and Chief Operating Officer (COO), Lab Operations
Cardoza joins AccuraGen following a 12-year tenure at NeoGenomics Laboratories where he served as Chief Financial Officer (CFO) from 2009-2018; President, Pharma Services Division from 2018-2021; and as President and Chief Operating Officer (COO), Lab Operations from 2021-2022.
Jan 1, 2022 | huntscanlon.comCancer research company, insurance agency lease at SkySong
Office leasing activity continues in the Scottsdale area despite the continuing pandemic. One of the new tenants at SkySong is NeoGenomics Inc., a publicly-traded cancer research firm.
Dec 29, 2021 | The Business JournalsNeogenomics Inc has issues with handling and use of their data through its Notice of Privacy Practices
In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through its Notice of Privacy Practices, and has invested in leading technologies to ensure the data Bestfortmyersrealestate maintain is secured at all times.
Jan 1, 2021 | biospace.comNeogenomics Inc partnered with Eli Lilly & Co. on Jun 9th 20'.
NeoGenomics announced on Tuesday a partnership with Lilly Oncology aimed at molecular testing for thyroid cancer patients.
Jan 1, 2020 | genomeweb.comCharles Schwab Investment Management, Inc. invests into Neogenomics Inc
Charles Schwab Investment Management invested 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO).
Jan 1, 2019 | whatsonthorold.comNeogenomics Inc receives financing of $5.3M in IPO
Founded in 2014, Dent and his management team made up largely of former NeoGenomics have raised $5.3 million in capital through private investments, an IPO and institutional funding.
Jan 1, 2019 | businessobserverfl.comMorgan Stanley invests into Neogenomics Inc
Morgan Stanley invested 0% in NeoGenomics, Inc. (NASDAQ:NEO).
Jan 1, 2018 | whatsonthorold.comNeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.
May 18, 1990 | Yahoo Finance